NCT05853965View on ClinicalTrials.gov

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 28, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Multiple MyelomaMultiple Myeloma in Relapse
Interventions
DRUG

Belantamab mafodotin, Venetoclax

Belantamab mafodotin (IV) Venetoclax (PO)

Trial Locations (5)

20246

RECRUITING

University Medical Center Hamburg-Eppendorf, Hamburg

Unknown

RECRUITING

Klinikum Chemnitz, Chemnitz

RECRUITING

Uniklinik Heidelberg, Heidelberg

RECRUITING

UKSH Lübeck, Lübeck

RECRUITING

Uniklinkum Ulm, Ulm

All Listed Sponsors
lead

Universitätsklinikum Hamburg-Eppendorf

OTHER